Adoptive immunotherapy of ovarian carcinoma with BS-MAb-targeted lymphocytes: A multicenter study

R. L.H. Bolhuis; C. H.J. Lamers; S. H. Goey; A. M.M. Eggermont; J. B.M.Z. Trimbos; G. Stoter; A. Lanzavecchia; E. Di Re; S. Miotti; F. Raspagliesi; L. Rivoltini; M. I. Colnaghi

Adoptive immunotherapy of ovarian carcinoma with BS-MAb-targeted lymphocytes: A multicenter study

R. L.H. Bolhuis, C. H.J. Lamers, S. H. Goey, A. M.M. Eggermont, J. B.M.Z. Trimbos, G. Stoter, A. Lanzavecchia, E. Di Re, S. Miotti, F. Raspagliesi, L. Rivoltini, M. I. Colnaghi

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

116 Citaten (Scopus)

Samenvatting

A bispecific monoclonal antibody (bs-MAb) (OC/TR) was produced in large quantities for the intraperitoneal (i.p.) treatment of ovarian cancer. The bs-MAb recognizes the folate-binding protein on ovarian cancer cells on the one hand and the CD3 activation site on T lymphocytes on the other. T lymphocytes were expanded ex vivo, targeted with OC/TR in vitro and administered to the i.p. cavity in the presence of soluble OC/TR. All patients developed human anti-mouse-antibodies (HAMA). In the Dutch study, 2 complete remissions (CR) were seen, 2 partial regressions (PR), 1 stable disease (SD) and 1 progressive disease (PD). In the Italian study 3 CR, 1 PR, 1 SD and 2 PD were seen.

Originele taal-2	Engels
Pagina's (van-tot)	78-81
Aantal pagina's	4
Tijdschrift	International Journal of Cancer
Nummer van het tijdschrift	SUPPL. 7
Status	Gepubliceerd - 1992
Extern gepubliceerd	Ja

Citeer dit

@article{a7d1e388ab8b46c8affe64701ab587b6,

title = "Adoptive immunotherapy of ovarian carcinoma with BS-MAb-targeted lymphocytes: A multicenter study",

abstract = "A bispecific monoclonal antibody (bs-MAb) (OC/TR) was produced in large quantities for the intraperitoneal (i.p.) treatment of ovarian cancer. The bs-MAb recognizes the folate-binding protein on ovarian cancer cells on the one hand and the CD3 activation site on T lymphocytes on the other. T lymphocytes were expanded ex vivo, targeted with OC/TR in vitro and administered to the i.p. cavity in the presence of soluble OC/TR. All patients developed human anti-mouse-antibodies (HAMA). In the Dutch study, 2 complete remissions (CR) were seen, 2 partial regressions (PR), 1 stable disease (SD) and 1 progressive disease (PD). In the Italian study 3 CR, 1 PR, 1 SD and 2 PD were seen.",

author = "Bolhuis, {R. L.H.} and Lamers, {C. H.J.} and Goey, {S. H.} and Eggermont, {A. M.M.} and Trimbos, {J. B.M.Z.} and G. Stoter and A. Lanzavecchia and {Di Re}, E. and S. Miotti and F. Raspagliesi and L. Rivoltini and Colnaghi, {M. I.}",

year = "1992",

language = "English",

pages = "78--81",

journal = "International Journal of Cancer",

issn = "0020-7136",

publisher = "Wiley-Liss Inc.",

number = "SUPPL. 7",

}

TY - JOUR

T1 - Adoptive immunotherapy of ovarian carcinoma with BS-MAb-targeted lymphocytes

T2 - A multicenter study

AU - Bolhuis, R. L.H.

AU - Lamers, C. H.J.

AU - Goey, S. H.

AU - Eggermont, A. M.M.

AU - Trimbos, J. B.M.Z.

AU - Stoter, G.

AU - Lanzavecchia, A.

AU - Di Re, E.

AU - Miotti, S.

AU - Raspagliesi, F.

AU - Rivoltini, L.

AU - Colnaghi, M. I.

PY - 1992

Y1 - 1992

N2 - A bispecific monoclonal antibody (bs-MAb) (OC/TR) was produced in large quantities for the intraperitoneal (i.p.) treatment of ovarian cancer. The bs-MAb recognizes the folate-binding protein on ovarian cancer cells on the one hand and the CD3 activation site on T lymphocytes on the other. T lymphocytes were expanded ex vivo, targeted with OC/TR in vitro and administered to the i.p. cavity in the presence of soluble OC/TR. All patients developed human anti-mouse-antibodies (HAMA). In the Dutch study, 2 complete remissions (CR) were seen, 2 partial regressions (PR), 1 stable disease (SD) and 1 progressive disease (PD). In the Italian study 3 CR, 1 PR, 1 SD and 2 PD were seen.

AB - A bispecific monoclonal antibody (bs-MAb) (OC/TR) was produced in large quantities for the intraperitoneal (i.p.) treatment of ovarian cancer. The bs-MAb recognizes the folate-binding protein on ovarian cancer cells on the one hand and the CD3 activation site on T lymphocytes on the other. T lymphocytes were expanded ex vivo, targeted with OC/TR in vitro and administered to the i.p. cavity in the presence of soluble OC/TR. All patients developed human anti-mouse-antibodies (HAMA). In the Dutch study, 2 complete remissions (CR) were seen, 2 partial regressions (PR), 1 stable disease (SD) and 1 progressive disease (PD). In the Italian study 3 CR, 1 PR, 1 SD and 2 PD were seen.

UR - http://www.scopus.com/inward/record.url?scp=0026494425&partnerID=8YFLogxK

M3 - Article

C2 - 1428412

AN - SCOPUS:0026494425

SN - 0020-7136

SP - 78

EP - 81

JO - International Journal of Cancer

JF - International Journal of Cancer

IS - SUPPL. 7

ER -

Adoptive immunotherapy of ovarian carcinoma with BS-MAb-targeted lymphocytes: A multicenter study

Samenvatting

Vingerafdruk

Citeer dit